Studying Cytomegalovirus & Congenital Hearing Loss in Infants
“Blindness separates people from things; deafness separates people from people.”—Helen Keller
Our research team is a unique, truly translational bench to bedside program dedicated to treat cytomegalovirus (CMV).
The clinical branch is focused on the role of valganciclovir for congenitally infected (cCMV) infants with isolated sensorineural hearing loss. We are conducting an NIH funded multi-institutional clinical trial to address this question (ValEAR CMV trial). Our laboratory is particularly interested in understanding the mechanisms underlying CMV induced hearing loss.